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ABSTRACT 29 
 30 
High levels of uric acid in urine and serum can be indicative of hypertension, and the 31 
pregnancy related condition, preeclampsia. We have developed a simple, cost-effective, 32 
portable surface enhanced Raman scattering (SERS) approach for the routine analysis of uric 33 
acid at clinically relevant levels in urine patient samples. This approach, combined with 34 
standard additions method (SAM), allows for the absolute quantification of uric acid directly 35 
in a complex matrix such as that from human urine. Results are highly comparable and in 36 
very good agreement with HPLC results, with an average <9% difference in predictions 37 
between the two analytical approaches across all samples analysed, with SERS demonstrating 38 
a 60-fold reduction in acquisition time compared with HPLC. For the first time, clinical pre-39 
preeclampsia patient samples have been used for quantitative uric acid detection using a 40 
simple, rapid colloidal SERS approach without the need for complex data analysis. 41 
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INTRODUCTION 60 
 61 
Preeclampsia is a hypertension disorder that can occur in pregnant women and is a primary 62 
cause for maternal morbidity and mortality worldwide, mainly in developing countries, with 63 
2-5% of pregnancies affected.1-3 The cause of preeclampsia remains unknown and even 64 
predicting which women are susceptible/have an increased risk of developing the condition is 65 
problematic.4,5 Moreover, when preeclampsia appears in the second or third trimester, there 66 
are no treatments available other than premature delivery of the baby,6 and those babies born 67 
are exposed to an increased risk of developing hypertension, heart disease and diabetes1,7,8. 68 
Currently, diagnosis of preeclampsia is a challenge as it relies on non-specific signs of the 69 
disease9; commonly associated symptoms include raised blood pressure and elevated protein 70 
levels (proteinuria) in the urine and so blood tests and urine protein measurement tests are 71 
often performed.10  72 
Uric acid has been identified as an important biomarker for various diseases such as 73 
cardiovascular diseases, gout, renal diseases and preeclampsia.11-15 Uric acid is the end 74 
product of the metabolic breakdown of purine nucleotides and in normal circumstances, 75 
concentrations range from 3.5-7.0 mg/dL in the blood and from 16-100 mg/dL per 24 h in 76 
urine.16 Moreover, elevated uric acid levels (referred to as hyperuricemia) in urine and serum 77 
has been associated with preeclampsia, with levels greater than 0.4 mM indicating severe 78 
preeclampsia.17  79 
Colorimetric enzymatic assays, liquid chromatography and capillary electrophoresis 80 
methodologies have been reported for uric acid detection; however, associated disadvantages 81 
include that these tests are often only applicable to late-stage preeclampsia, involve time 82 
consuming assay based tests, expensive enzymes, sophisticated instrumentation and 83 
equipment and often lack sensitivity. Therefore, there is a great need for a rapid, inexpensive, 84 
routine, diagnostic test to aid early uric acid detection, thus allowing hyperuricemia 85 
conditions to be properly monitored and managed to prevent further health implications.18,19  86 
Surface enhanced Raman scattering (SERS) has increasingly been employed for use in 87 
quantification of biologically relevant molecules20-24. SERS is the dramatic enhancement of 88 
Raman signals when an analyte is in close proximity/absorbed onto a nanoscale rough 89 
metallic surface, with typical enhancements of 104-106 observed. It is an attractive approach 90 
for disease diagnosis as it yields molecular specific information, is label-free, has the ability 91 
to be performed in aqueous environments and has high sensitivity with low analyte 92 
concentration detection (down to fM level and single molecule detection).25-28  93 
Raman spectroscopy also offers several advantages including its ease-of-use along with 94 
portability29 leading to the ability to develop point-of-care analysis systems for on-site Point-95 
and-Shoot analyses.30 Recently, there have been several Raman spectroscopy based 96 
approaches, mostly utilising electrochemical surface enhanced Raman (E-SERS), to measure 97 
uric acid detection. However, these studies have demonstrated problems in establishing 98 
reliable, quantitative detection of uric acid at clinically relevant concentrations31, have 99 
employed complex sample make up32,33 and used complex data analysis34. In all cases, the 100 
studies were not performed in real-life situations, i.e. biological fluids, but instead were 101 
performed in either urine stimulant, synthetic urine or water.35 102 
 103 
In this paper, we present an optimised SERS approach for uric acid detection in human urine 104 
from clinical pre-preeclamptic patients (urine samples collected between 11-14 weeks 105 
gestation) using a portable, easy-to-use Raman instrument. As uric acid is already present in 106 
urine, our approach involves using the well-known standard additions method (SAM), as well 107 
as HPLC analysis for additional benchmarking (see supporting information Figure S1). In 108 
SAM, a series of samples are analysed involving spiking in known amounts of uric acid in 109 
increasing concentrations whereby the subsequent calibration curve is used to determine the 110 
unknown concentration of uric acid in the original (undiluted) sample. We have performed 111 
this approach on 21 clinical samples, of which, 11 were performed in triplicate analysis to 112 
establish reproducibility, affording direct quantification of the target analyte within the 113 
sample thus accounting for the complex sample matrix. To the best of our knowledge, this 114 
simple colloidal uric acid detection approach in clinical patient samples is the first study of its 115 
kind. 116 
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RESULTS AND DISCUSSION 132 
 133 
SERS optimisation 134 
 135 
We have previously established optimised conditions for uric acid SERS detection within an 136 
enzymatic system by varying certain parameters such as colloid type, pH, concentration, time 137 
aggregation and aggregating agent.8 However, uric acid detection in a more complex matrix, 138 
such as urine which is a molecular milieu of small molecules, organic acids and ions as well 139 
as proteins, required a slightly different set of conditions. Optimised conditions were 140 
established using a pooled QC urine sample (from all 58 patient samples), and as before 141 
hydroxylamine-reduced silver colloid was the optimum SERS substrate to use, at pH 7.6, 142 
without the need for an aggregating agent. The aggregation time was slightly modified, with 143 
optimum uric acid detection achieved after 3.5 min (± 1 min) aggregation (see Figure 1 and 144 
supporting information Figures S2 and S3). Table 1 shows the tentative SERS band 145 
assignments for uric acid (see supporting information Figure S4 for normal Raman spectra 146 
of uric acid (solid) which aided in band assignment).8,13,35 147 
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Figure 1 Annotated mean averaged SERS spectra (n = 5) of uric acid. SERS spectra were 
obtained for 20 s, at 25 µM (dissolved in water) using 200 μL of hydroxylamine reduced 
silver colloid, potassium phosphate buffer at pH 7.6; measurements were made 3 min after 
aggregation. 
 161 
 162 
 163 
 164 
A concern for the analysis in human urine was the effect the pH of individual samples would 165 
have on the SERS spectrum as well as any potential difference in how the target analyte 166 
would interact with the silver surface. After dilution, the pH of the urine samples varied 167 
considerably from 4.45 – 9.3, meaning uric acid would be in different ionisation states and 168 
consequently interact with the surface differently, generating sub-optimal SERS spectra, 169 
ultimately not representing the actual concentration in the sample. To overcome this and to 170 
ensure the urine sample had an overall pH that coincided with optimal uric acid detection, the 171 
sample environment was carefully modified. A potassium phosphate buffer at pH 7.6 was 172 
added to the colloid and urine, as well as the uric acid spiked in to the sample for the standard 173 
additions measurements. Therefore, after all constituents were added (i.e. urine, buffer, 174 
spiked uric acid and colloid), the overall sample pH for all patients varied from pH 7.2 – 8. 175 
This meant that in all analyses uric acid was predominantly in its negative 1 ionisation state 176 
and would have the same affinity for the colloidal surface thus affording more reproducible 177 
and optimal SERS uric acid detection for all samples (see supporting information Figure 178 
Raman Shift (cm
-1
) SERS Peak (cm
-1
) Tentative band assignment
[8,13,35] 
380 (mw) - - 
-  508 (vwsh) C-N-C ring vibrations 
- 534 (vw)  
626 (w) 640 (s) Skeletal ring deformation 
705 (w)  730 (w) N-H bending 
783 (m) 812 (m) Ring vibration 
884 (w)  889 (m) N-H bending 
998 (s) 1017 (w) Ring vibrations 
1033 (vs) - -
1122 (s)  1134 (vs) C-N 
1233 (s)  1206 (m) N-C-C stretching and bending 
1289 (s) 1266 (w) - 
1355 (w) 1369 (s) C-O  
- 1515 (vwsh) Asymmetric deformation NH3 
1406 (vs) - - 
1499 (s) - - 
1596 (m) 1554 (m) C-N 
1679 (vs) 1684 (s) - 
Table 1: Band assignments for normal Raman (solid) and tentative SERS (25 µM solution) 
band assignments for the Uric Acid 
ν –stretching, b-bending, R-ring; trigd-trigonal deformation, s-strong, vs-very strong, m-medium, 
w-weak, vw-very weak 
S3). Moreover, the presence of additional buffer (i.e. 75 µL) in the sample make up was 179 
necessary as it also acted as an aggregating agent to help stabilise the SERS response, 180 
especially for samples where low uric acid (or none, as in the blank) was spiked in. 181 
 182 
Standard additions method (SAM) approach 183 
 184 
Previously for quantifying uric acid within a mixture (in terms of monitoring 185 
biotransformation(s) involving three analytes) we used various chemometric approaches such 186 
as partial least squares regression (PLSR) and multivariate curve resolution-alternating least 187 
squares (MCR-ALS).8 However, these data analysis methods are not suitable for quantifying 188 
analytes in complex matrices where the sample matrix actually contributes to the analytical 189 
signal (i.e., when uric acid is already present in urine). Standard additions method (SAM) 190 
works by spiking in known amounts of standard, in this case uric acid, and plotting peak area 191 
(of a characteristic peak, viz. 1134 cm-1) against the concentration of the standard spiked in, 192 
thus yielding a straight line (y = mx + b; where m and b are the slope of the line and 193 
y-intercept, respectively). From there, the concentration of the analyte can be determined 194 
from the point at which the extrapolated line crosses the concentration axis (x) at zero signal 195 
(i.e. where y = 0 and thus x = -b/m such that the concentration = b/m).36,37 196 
A prerequisite in order to use SAM is a linear relationship between the concentration and the 197 
SERS signal of uric acid. From performing a concentration profile (see supporting 198 
information Figure S2a), the linear concentration range was determined to be between 1 – 199 
100 µM). Therefore, for some samples, dilution of the initial urine sample was performed to 200 
ensure that on spiking in a known amount of standard, this linear concentration range was 201 
retained. Notably, in cases of saturation, comparably lower SERS signals are observed for 202 
higher analyte concentrations, as seen beyond 100 µM, and a non-linear relationship is 203 
observed. We also had to consider the effect of the concentration-dependence on the 204 
orientation of the target molecule on the colloidal surface. We noticed that below 5 µM, 205 
although still part of the linear relationship, the SERS spectrum of uric acid changed slightly, 206 
in terms of intensity and broadness of certain peaks, indicating the orientation of the analyte 207 
molecule on the surface was probably different. Therefore, for this reason, 5 - 100 µM was 208 
determined to be the optimum total concentration range of uric acid in the urine sample, 209 
taking into account spiking of standard and dilution factors. 210 
 211 
Sample selection and SAM Analysis  212 
 213 
Rather than measure all samples, 21 samples from the 58 human urine samples were 214 
randomly selected for comparative SERS and HPLC SAM analysis – we ensured that the 215 
samples selected covered the entire uric acid concentration range. The characteristic peak for 216 
uric acid used in the analysis was at 1134 cm-1, corresponding to the C-N vibration. Table 2 217 
shows a summary of the results from each analytical approach along with the associated 218 
percentage differences.  As an example, for sample 18, HPLC results predicted a uric acid 219 
concentration of 172 µM, compared to 186 µM predicted from SERS, a difference of 7.5%. 220 
Overall, for all samples analysed, the percentage difference between the two analytical 221 
approaches ranged from 0.8% (sample 20) to 19.1% (sample 40), with the average percentage 222 
difference being 8.4 %. This is very encouraging considering the uric acid concentration 223 
range was extensive (starting from around 65 µM to 670 µM) meaning this approach could 224 
be extended to target other uric acid related diseases (i.e. those related to low concentration of 225 
uric acid (hypouricemia) as well as elevated uric acid levels (hyperuricemia) such as in 226 
preeclampsia). 227 
 228 
 229 
 230 
 231 
NB Dilution factors taken into account. See ‘Preparation of urine for HPLC and SERS analysis’ in Supporting 232 
Information. 233 
 234 
We next wanted to address the reproducibility of this SERS approach. Eleven of the 21 235 
samples were randomly selected for triplicate HPLC and SERS analysis. For the latter, this 236 
meant using a different colloidal batch for each replicate performed (see supporting 237 
information Figure S5). In general, batch-to-batch variation and reproducibility of SERS 238 
enhancements is a key discussion point within the Raman community.38-41 Groups report 239 
noticeable discrepancies in results due to variations in colloidal batches, colloid 240 
concentrations and nanoparticle aggregation – all of which can result in inconsistent 241 
enhancements. However, we have demonstrated using these optimised set of conditions for 242 
uric acid detection in urine that we can produce consistent, reliable results that are in good 243 
Sample HPLC (μM) 
SERS 
(μM) Difference Sample 
HPLC 
(μM)
SERS 
(μM) Difference 
QC (n=58) 190.3 181.1 4.8% 26 215.0 182.9 14.9% 
1 274.9 266.6 3.1% 31 548.5 601.6 8.8% 
4 112.9 111.8 1.0% 36 206.9 187.7 10.2% 
5 119.4 135.1 11.6% 40 219.2 184.0 19.1% 
9 64.5 73.2 11.9% 41 309.8 294.2 5.3% 
12 91.5 88.4 3.4% 44 196.6 188.7 4.0% 
14 70.1 73.1 4.1% 47 183.0 157.5 16.2% 
16 511.2 561.6 9.9% 49 679.4 665.5 2.1% 
18 172.0 186.0 7.5% 52 249.5 233.8 6.7% 
20 151.9 153.1 0.8% 53 126.3 117.4 7.1% 
22 234.6 199.3 15.0% 55 345.8 301.6 12.8% 
Table 2: Summary of results for all samples analysed: HPLC (µM), SERS (µM) and the 
associated percentage differences between the two analytical approaches 
agreement and comparable to HPLC results, the ‘gold standard’ in this case and used for 244 
benchmarking (see Table 3). 245 
As an example, sample 20 was subjected to triplicate analysis (see supporting information 246 
Figure S6). The average percentage difference between the HPLC and SERS results was just 247 
over 1.5% across the three replicates. The standard deviation (SD) for SERS results was 4.1 248 
(compared to 3.3 for HPLC) and the relative standard deviations (RSD) were 2.1 and 2.7% 249 
for HPLC and SERS respectively. These results are excellent in terms of accuracy (difference 250 
between HPLC and SERS), precision (SD for these repeat measurements) and overall 251 
reproducibility. To emphasise this further, the average percentage difference for triplicate 252 
analysis between the two analytical approaches was 7.2%, with the average SD and RSD for 253 
SERS being 12.8 and 6.7% and for HPLC, 6.3 and 3.3% respectively. 254 
 255 
 256 
 257 
 258 
 259 
 260 
 261 
To confirm further how excellent the agreement of data are between the two analytical 262 
approaches, Figure 2a) shows a HPLC versus SERS plot for all 21 analyses, reflecting a very 263 
good linear trend with an R2 of 0.9792. In addition, Figure 2b) is a plot of percentage 264 
difference (from HPLC – SERS predictions) against HPLC predicted concentration for all 265 
samples analysed. The ‘randomness’ of the plot (i.e. both positive and negative differences) 266 
indicates that there is no systematic bias in the analysis. Notably, there are less samples 267 
analysed at high uric acid levels, and ideally we would want an even spread of samples across 268 
Sample HPLC (µM) SD (±) RSD (±) SERS (µM) SD (±) RSD (±) Difference 
1 274.9 13.6 5.0% 266.6 17.4 6.5% 3.1% 
4 112.9 3.8 3.4% 111.8 9.6 8.6% 1.0% 
5 119.4 1.5 1.3% 135.1 11.1 8.3% 11.6% 
12 91.5 6.0 6.5% 88.4 9.2 10.5% 3.4% 
20 152.3 3.2 2.1% 153.1 4.1 2.7% 1.5% 
36 206.9 5.0 2.4% 187.7 8.4 4.5% 10.2% 
40 219.2 1.6 0.7% 184.0 12.5 6.8% 19.1% 
41 309.8 10.8 3.5% 294.2 16.8 5.7% 5.3% 
47 183.0 6.1 3.3% 157.5 13.4 8.5% 16.2% 
49 679.4 9.4 4.2% 665.5 16.5 2.5% 2.1% 
52 249.5 8.5 3.4% 233.8 22.1 9.4% 6.7% 
Control* 51.0 0.7 1.4% 53.9 4.6 8.5% 7.8% 
Table 3: Summary of results for samples involving triplicate analysis including associated 
percentage differences between the two analytical approaches, standard deviations (SD) 
and relative standard deviations (RSD)  
*Control is to establish overall errors associated with each technique. 50 µM (i.e. known concentration) was 
spiked into blank 
 
The average difference between the two analytical approaches was 7.2%. The average SD and RSD for SERS 
was 12.8 and 6.7% and for HPLC, 6.3 and 3.3% respectively. 
the entire uric acid concentration range to demonstrate fully how applicable this SERS 269 
approach is. However, these samples are real, clinical pre-preeclampsia samples and hence 270 
this is reflected by the uric acid concentrations observe 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
 279 
 280 
 281 
 282 
 283 
Noticeably, SERS results have slightly higher SD and RSD throughout the samples analysed. 284 
However, the reduction in acquisition times for SERS analysis largely compensates and 285 
outweighs this. In total, SAM HPLC takes 140 min (7 samples × 20 min HPLC trace) for uric 286 
acid prediction for each sample. Comparatively, SAM SERS analysis takes 140 s (7 samples 287 
× 20 s SERS acquisition), a 60-fold reduction and yet results are in very good agreement and 288 
highly comparable. There is only on average 8.4% difference for all samples analysed. There 289 
was on average 7.2% difference for the triplicate analysis indicating that the precision and 290 
accuracy were similar. Moreover, if one considers the actual associated error with each 291 
analytical approach (see Table 2) - for HPLC there are associated SD and RSD of 0.7 and 292 
1.4% and for SERS 4.6 and 8.5% respectively - there is overlap and leeway in the results 293 
between the two analytical approaches, making this SERS approach a highly attractive 294 
alternative that could be used in clinical settings. Finally on this point, the cost of the analysis 295 
is comparable, as HPLC apparatus include instrument costs and consumables, which are 296 
equivalent to low-cost portable and indeed hand-held Raman spectrometers plus cost of 297 
colloid and reagents. 298 
 299 
 300 
 301 
Figure 2 a) A plot of predictions from HPLC vs. SERS for all samples (including replicates) 
with an R
2
 of 0.9792 indicating results are in very good agreement. b) A plot of percentage 
difference (from HPLC – SERS predictions) against HPLC predicted concentration for all 
samples analysed, indicating that there is no systematic bias in the analysis.  
ONLINE METHODS 302 
Full experimental details are provided in the supporting information ‘Supplementary 303 
Methods’ section. 304 
Materials. All chemical reagents were of analytical grade and used with no additional 305 
purification unless otherwise stated.  306 
Human urine samples were kindly donated by Prof B. Thilaganathan from St George’s, 307 
University of London & St George’s University Hospitals NHS Foundation Trust Clinical 308 
Sciences Research Centre. Written informed consent was obtained from each study 309 
participant and the study conformed to the principles set out in the WMA Declaration of 310 
Helsinki and the NIH Belmont report. The study was approved by Wandsworth Local 311 
Research Ethics Committee. 312 
Processing of Urine. For optimisation of uric acid detection in urine, we used a pooled urine 313 
stock from 58 different patients (QC n=58). For each urine sample, a protein crash method 314 
was performed using methanol (at RT). 150 μL urine was aliquoted in Eppendorf tubes. 600 315 
μL methanol was added to this, and centrifuged for 15 min at 13,500 ×g. 400 μL was 316 
removed from the supernatant into a new Eppendorf tube and concentrated for ~ 4 h using an 317 
Eppendorf Vacufuge Concentrator 5301 (Eppendorf, UK). Once all methanol had been 318 
removed, the sample was re-suspended in 150 μL water and vortexed for 5 s.  319 
Sample Selection. All urine samples from the 58 patients were processed as described above. 320 
For the QC sample used in optimising various parameters for SERS detection, all 58 urine 321 
samples were pooled. 21 of these 58 urine samples were randomly selected to cover the entire 322 
uric acid concentration range to remove any measurement redundancy. Triplicate analyses 323 
were then performed on 11 of these 21 samples to establish reproducibility. 324 
Sample preparation. 3.5×10-4 M uric acid stock solution was prepared in 1M potassium 325 
phosphate buffer solution at pH 7.6. Samples for individual analyses were then prepared as 326 
follows: For SERS samples, 200 µL of hydroxylamine reduced Ag colloid (HRSC), 75 µL 327 
potassium phosphate buffer at pH 7.6 and 125 µL urine was added to a glass vial. The silver 328 
colloid was prepared according to the method of Leopold and Lendl.42 For HPLC samples, 329 
the same procedure was followed except water was added instead of colloid. For SAM 330 
sample preparation the concentration of uric acid spiked into each urine sample was 0, 8.5, 331 
16.7, 24.4, 31.8, 38.9, 45.7 and 55.3 µM. All dilution factors were taken into account when 332 
predicting final uric acid concentrations.  333 
Raman Instrumentation. A DeltaNu Advantage 200A portable Raman spectrometer 334 
(DeltaNu, Laramie, WY, USA) was used for collection of spectra using a HeNe 633 nm laser 335 
with ∼3 mW on the sample. 336 
CONCLUSION 337 
 338 
There is a real urgent unmet need for early diagnosis of preeclampsia in pregnant women. We 339 
have demonstrated a SERS based approach to measure uric acid in pre-preeclamptic urine 340 
samples which yields absolute quantitation. In combination with the well-known SAM 341 
approach, uric acid concentrations have been predicted in urine samples from 21 different 342 
patients, and benchmarked against HPLC. It is highly notable that there is a 60-fold reduction 343 
in acquisition time when employing this SERS-based approach, and yet the average 344 
difference between the two analytical approaches is less than 9%. Furthermore, we have 345 
demonstrated excellent reproducibility, with 11 of these samples performed in triplicate 346 
analysis using different colloidal batches (for each replicate) highlighting its use for 347 
applications in rapid, routine detection of uric acid. We believe this new SERS-SAM 348 
analytical approach could easily be translated into an on-site, diagnostic tool for early 349 
diagnosis of preeclampsia and indeed other disease where quantification of uric acid is 350 
needed.  351 
 352 
 353 
 354 
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